Literature DB >> 10028110

Bacterial vaginosis: review of treatment options and potential clinical indications for therapy.

M R Joesoef1, G P Schmid, S L Hillier.   

Abstract

We reviewed data on the treatment of bacterial vaginosis published from 1993 through 1996. For nonpregnant women, we recommend use of metronidazole (500 mg orally twice daily for 7 days), clindamycin vaginal cream (2%, once daily for 7 days), or metronidazole vaginal gel (0.75%, twice daily for 5 days) as the preferred treatment for bacterial vaginosis. For pregnant high-risk women (women with a prior preterm birth), the objective of the treatment is to prevent adverse outcomes of pregnancy, in addition to relief of symptoms. Thus, systemic therapy for possible subclinical upper tract infection as well as medication that has been studied in pregnant women are preferable. Therefore, we recommend metronidazole (250 mg orally three times a day for 7 days). For pregnant low-risk women (women without a prior preterm birth) with symptomatic disease, the main objective of the treatment is to relieve symptoms. We recommend metronidazole (250 mg orally three times a day for 7 days). Data do not support routine treatment of male sex partners.

Entities:  

Mesh:

Year:  1999        PMID: 10028110     DOI: 10.1086/514725

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  26 in total

1.  Characteristics and pregnancy outcomes of pregnant women asymptomatic for bacterial vaginosis.

Authors:  Deborah B Nelson; Scarlett Bellamy; Bonnie A Clothier; George A Macones; Irving Nachamkin; Althea Ruffin; Lynne Allen-Taylor; Frank K Friedenberg
Journal:  Matern Child Health J       Date:  2007-06-02

2.  Association of Mobiluncus curtisii with recurrence of bacterial vaginosis.

Authors:  Michelle C Meltzer; Renee A Desmond; Jane R Schwebke
Journal:  Sex Transm Dis       Date:  2008-06       Impact factor: 2.830

3.  PURLs: Help for recurrent bacterial vaginosis.

Authors:  Kohar Jones; Bernard Ewigman
Journal:  J Fam Pract       Date:  2011-02       Impact factor: 0.493

4.  A new anti-microbial combination prolongs the latency period, reduces acute histologic chorioamnionitis as well as funisitis, and improves neonatal outcomes in preterm PROM.

Authors:  JoonHo Lee; Roberto Romero; Sun Min Kim; Piya Chaemsaithong; Chan-Wook Park; Joong Shin Park; Jong Kwan Jun; Bo Hyun Yoon
Journal:  J Matern Fetal Neonatal Med       Date:  2015-09-16

5.  Tinidazole vs metronidazole for the treatment of bacterial vaginosis.

Authors:  Jane R Schwebke; Renee A Desmond
Journal:  Am J Obstet Gynecol       Date:  2010-12-17       Impact factor: 8.661

Review 6.  Drug treatment of nonviral sexually transmitted diseases: specific issues in adolescents.

Authors:  C E Lehmann; F M Biro
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

7.  Risk Factors for Postcesarean Maternal Infection in a Trial of Extended-Spectrum Antibiotic Prophylaxis.

Authors:  Kim A Boggess; Alan Tita; Victoria Jauk; George Saade; Sherri Longo; Erin A S Clark; Sean Esplin; Kristin Cleary; Ronald Wapner; Kelli Letson; Michelle Owens; Sean Blackwell; Carmen Beamon; Jeffrey M Szychowski; William Andrews
Journal:  Obstet Gynecol       Date:  2017-03       Impact factor: 7.661

8.  Low prevalence of cervical infections in women with vaginal discharge in west Africa: implications for syndromic management.

Authors:  J Pépin; S Deslandes; N Khonde; D F Kintin; S Diakité; M Sylla; H Méda; F Sobéla; C Asamoah-Adu; T Agyarko-Poku; E Frost
Journal:  Sex Transm Infect       Date:  2004-06       Impact factor: 3.519

Review 9.  Managing recurrent bacterial vaginosis.

Authors:  J Wilson
Journal:  Sex Transm Infect       Date:  2004-02       Impact factor: 3.519

10.  Comparison of oral and vaginal metronidazole for treatment of bacterial vaginosis in pregnancy: impact on fastidious bacteria.

Authors:  Caroline M Mitchell; Jane E Hitti; Kathy J Agnew; David N Fredricks
Journal:  BMC Infect Dis       Date:  2009-06-10       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.